Skip to main content
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX-117
      • ARGX-118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us

Breadcrumb

  1. Home
  2. News

The Latest

News
March 4, 2021

argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update

Breda, the Netherlands
argenx today reported financial results for the full year 2020 and provided a fourth quarter business update.
Read

More Press Releases

News
February 25, 2021

argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update.
Read
News
February 5, 2021

argenx announces closing of global offering

argenx SE announced today the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary...
Read
News
February 4, 2021

argenx announces full exercise of underwriters’ option to purchase additional ADSs

argenx SE announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 468,750 additional ADSs in full on the same terms and conditions as the...
Read
Show more Press Releases

Media center

  • ARGX-118
  • CIDP
  • Cusatuzumab
  • Efgartigimod
  • Immune Thrombocytopenia
  • Myasthenia Gravis
  • Pemphigus Vulgaris
  • SIMPLE Antibody Platform
May 1, 2020
Making Asthma Crystal Clear
April 16, 2020
Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
April 13, 2020
ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels
April 8, 2020
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment
April 7, 2020
SIMPLE Antibody platform / DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops
  • Load more
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX-117
      • ARGX-118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
2021 © Argenx
Disclaimer
Privacy policy
You are now leaving the argenx web site

This link will take you to a site maintained by a third party, which is responsible for its contents.

OK